BRAF and cancer: Beyond anti-EGFR therapies in RAS/BRAF wild-type tumors, other targeted therapies have indeed emerged, including immune checkpoint inhibitors for deficient mismatch repair (dMMR) tumors, BRAF inhibition for BRAFV600E mutant, HER2 blockade in HER2-positive, and anti-KRAS G12C inhibitors in KRAS G12C mutant cancers (6PMID: 35472088).